| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/09/1998 | WO1998014433A1 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 04/09/1998 | WO1998014427A1 Nmda (n-methyl-d-aspartate) antagonists |
| 04/09/1998 | WO1998014216A2 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 04/09/1998 | WO1998014209A1 Oral administration of chicken yolk antibodies to treat disease |
| 04/09/1998 | WO1998014204A1 USES OF COMPOSITIONS WITH α-LACTALBUMEN BASE |
| 04/09/1998 | WO1998014202A1 Regulation of neural enzymes |
| 04/09/1998 | WO1998014186A1 Substances and their uses |
| 04/09/1998 | WO1998014177A1 Methods and compositions employing red yeast fermentation products |
| 04/09/1998 | WO1998014168A2 Dosage form providing a sustained and ascending drug release |
| 04/09/1998 | WO1998014162A1 Agent for acting upon the organism |
| 04/09/1998 | WO1998001549A3 Genetic sequences and proteins related to alzheimer's disease, and uses therefor |
| 04/09/1998 | WO1997045746A3 Prion protein binding proteins and uses thereof |
| 04/09/1998 | DE19637518A1 PTX-sensitive G-Proteine, ihre Herstellung und Verwendung PTX-sensitive G-proteins, their production and use |
| 04/09/1998 | CA2574049A1 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 04/09/1998 | CA2268020A1 Uses of compositions with .alpha.-lactalbumen base |
| 04/09/1998 | CA2267523A1 Regulation of neural enzymes |
| 04/09/1998 | CA2267421A1 Oral administration of chicken yolk antibodies to treat disease |
| 04/09/1998 | CA2267340A1 Methods and compositions employing red yeast fermentation products |
| 04/09/1998 | CA2266510A1 N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics |
| 04/09/1998 | CA2265449A1 Disease associated protein tyrosine phosphatases |
| 04/09/1998 | CA2265447A1 Novel human phospholemman-like protein |
| 04/09/1998 | CA2236914A1 Interleukin-1.beta. converting enzyme like cysteine protease |
| 04/09/1998 | CA2217846A1 A combination preparation containing tramadol and a calcium channel antagonist |
| 04/08/1998 | EP0834565A2 A G-protein coupled receptor HUVCT36 |
| 04/08/1998 | EP0834563A2 Human 7-transmembrane receptor, member of the chemokine receptor family, named Strl-33 |
| 04/08/1998 | EP0834508A1 Substituted biphenyl or phenylpyridine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 04/08/1998 | EP0834316A1 Use of sulbutiamine for the treatment of psychomotor or psycho-intellectual problems |
| 04/08/1998 | EP0834313A1 Therapeutic treatment for central nervous system diseases associated with HIV infection |
| 04/08/1998 | EP0833935A1 Cell line producing analgesic compounds for treating pain |
| 04/08/1998 | EP0833820A1 Benzisoxazole and indazole derivatives as antipsychotic agents |
| 04/08/1998 | EP0833671A2 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| 04/08/1998 | EP0833664A1 Combination of a cyclooxygenase-2 inhibitor and a leukotriene b 4? receptor antagonist for the treatment of inflammations |
| 04/08/1998 | EP0833652A1 Novel kappa receptor selective opioid peptides |
| 04/08/1998 | EP0833639A1 Phenoxy piperazine derivatives for treating disorders of the dopamine system |
| 04/08/1998 | EP0833638A1 USE OF IMIDAZO 1,5-a]QUINOLONES AS NEUROPROTECTIVE AGENTS |
| 04/08/1998 | EP0833622A1 Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor |
| 04/08/1998 | EP0833612A1 New pharmaceutical composition with anaesthetic effect |
| 04/08/1998 | EP0715624B1 Process for the preparation of benzodiazepine compounds useful as antagonists of cck or of gastrine |
| 04/08/1998 | EP0706512B1 Acetamide derivatives and their use for modifying feeding behaviour modifiers |
| 04/08/1998 | EP0667852B1 Novel 3,3-diphenylpropylamines, their use and preparation |
| 04/08/1998 | CN1178533A Process for isolating galanthamine |
| 04/08/1998 | CN1178469A Treatment of cerebral ischemia and cerebral damage with neuroprotective agent |
| 04/08/1998 | CN1178462A Methods and pharmaceutical compostions employing desmethylselegiline |
| 04/08/1998 | CN1178461A Pharmaceutical compositions comprising monoamine oxidase B inhibitors |
| 04/08/1998 | CN1178119A Chinese medicinal preparation for senile dementia |
| 04/08/1998 | CN1037934C Pharmaceutical soft capsules containing lysne elonixiwate |
| 04/07/1998 | US5736578 Treatment of sleep disorders |
| 04/07/1998 | US5736575 Administering theanine (l-glutamic acid-gamma-ethylamide) to a mammal; stimulants |
| 04/07/1998 | US5736568 2-(aminoalkoxy) phenylalkylamines with antiinflammatory activity |
| 04/07/1998 | US5736562 Modify function of serotonin in mammals |
| 04/07/1998 | US5736560 Useful in the treatment of alzheimer's and parkinsons's diseases |
| 04/07/1998 | US5736558 4-(6-fluoro-1,2-benzisoxazolyl)-1 piperidinyl-propoxy-chromen-4-one-one-derivatives, their preparation and their use in the treatment of psychosis, schizophrenia and anxiety |
| 04/07/1998 | US5736556 Parkinson*s disease; antidepressants; antiobesity; antinarcolepsy; drug abruse |
| 04/07/1998 | US5736555 Hypotensive agents; fda orange book listed patent for azilsartan medoxomil |
| 04/07/1998 | US5736543 Benzoxazines for enhancing synaptic response |
| 04/07/1998 | US5736541 Slurrying impure material in anhydrous ethyl acetate, then crystallization yields pure stable drug for treatment of anxiety, psychological disorders and gastrointestinal disorders |
| 04/07/1998 | US5736515 Use of growth hormone for increasement of concentration of GH, IGF-I and IGFBP-3 in cerebrospinal fluid |
| 04/07/1998 | CA2146260C Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds |
| 04/07/1998 | CA2146259C Substituted benzylaminoquinuclidines |
| 04/07/1998 | CA2130116C Aminoacetylmercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| 04/07/1998 | CA2084193C 3-amino-2-aryl quinuclidines |
| 04/07/1998 | CA2073189C N-substituted azaheterocyclic carboxylic acids and a pharmaceutical composition |
| 04/07/1998 | CA2026775C Halo substituted aminotetralins |
| 04/07/1998 | CA2003441C Quinuclidine therapeutic agents |
| 04/02/1998 | WO1998013496A1 Chaperone fragments |
| 04/02/1998 | WO1998013489A1 Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation |
| 04/02/1998 | WO1998013369A1 Spiro-azacyclic derivatives, their preparation and their use as tachykinin antagonists |
| 04/02/1998 | WO1998013355A1 Heterocyclic esters and amides |
| 04/02/1998 | WO1998013349A2 Heteroaryloxyethylamines as 5-ht1a ligands |
| 04/02/1998 | WO1998013343A1 Heterocyclic thioesters and ketones |
| 04/02/1998 | WO1998013337A1 Novel phenoxyethylamine derivatives, method of preparation, application as medicine and pharmaceutical compositions containing same |
| 04/02/1998 | WO1998013054A1 A method for producing an extract from valeriana officinalis containing high levels of valerenic acid |
| 04/02/1998 | WO1998013046A1 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| 04/02/1998 | WO1998013044A1 Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors |
| 04/02/1998 | WO1998013029A1 Oral delayed immediate release formulation and method of preparation therefor |
| 04/02/1998 | WO1998013027A1 Coated particle formulation |
| 04/02/1998 | WO1998013001A1 Intranasal formulations for promoting sleep and method of using the same |
| 04/02/1998 | WO1998005292A3 Piperidine and piperazine derivatives and their use as muscarinic antagonists |
| 04/02/1998 | CA2602802A1 Heterocyclic thioesters and ketones |
| 04/02/1998 | CA2266898A1 Intranasal formulations for promoting sleep and method of using the same |
| 04/02/1998 | CA2266448A1 Coated particle formulation |
| 04/02/1998 | CA2266427A1 Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation |
| 04/02/1998 | CA2265950A1 Spiro-azacyclic derivatives and their use as therapeutic agents |
| 04/02/1998 | CA2264158A1 Pharmaceutical compositions and methods of treating compulsive disorders using naaladase inhibitors |
| 04/02/1998 | CA2264043A1 Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| 04/02/1998 | CA2263925A1 Heterocyclic esters and amides |
| 04/01/1998 | EP0832879A1 Process for preparing intermediates for thrombin inhibitors |
| 04/01/1998 | EP0832652A1 Process of extracting and purifying biologically effective ingredients from combined medicinal plants and their extract composition |
| 04/01/1998 | EP0832216A1 Fibroblast growth factor 15 |
| 04/01/1998 | EP0832215A1 Fibroblast growth factor 11 |
| 04/01/1998 | EP0832205A1 Method for identifying alzheimer's disease therapeutics using transgenic animal models |
| 04/01/1998 | EP0832203A1 Use of neuro-derived fetal cell lines for transplantation therapy |
| 04/01/1998 | EP0832099A1 Reversible cysteine protease inhibitors |
| 04/01/1998 | EP0832092A1 Orally active adenosine kinase inhibitors |
| 04/01/1998 | EP0832091A1 C-4' modified adenosine kinase inhibitors |
| 04/01/1998 | EP0832074A1 Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists |
| 04/01/1998 | EP0832064A1 5-aminoalkyl-2-(2-alkoxyphenyl)-pyrrole derivatives having affinity for dopamine d3 receptors and their use in the treatment of psychoses |
| 04/01/1998 | EP0831920A1 Novel cathepsin and methods and compositions for inhibition thereof |
| 04/01/1998 | EP0831883A1 Treatment of alzheimer disease by modulation of synapsins |
| 04/01/1998 | EP0831854A1 Oligonucleotides having phosphorothioate linkages of high chiral purity |